Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
2.140
-0.040 (-1.83%)
At close: May 22, 2024, 4:00 PM
2.100
-0.040 (-1.87%)
After-hours: May 22, 2024, 6:27 PM EDT
-1.83%
Market Cap 133.86M
Revenue (ttm) n/a
Net Income (ttm) -24.86M
Shares Out 62.55M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,108
Open 2.180
Previous Close 2.180
Day's Range 2.100 - 2.240
52-Week Range 1.050 - 4.190
Beta 1.05
Analysts Buy
Price Target 6.25 (+192.06%)
Earnings Date May 6, 2024

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also develop... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 23, 2016
Employees 28
Stock Exchange NASDAQ
Ticker Symbol CRVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $6.25, which is an increase of 192.06% from the latest price.

Price Target
$6.25
(192.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024

16 days ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

20 days ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced ...

20 days ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor

6 weeks ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Poster presentation unveils Corvus' next-generatio...

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mi...

4 months ago - GlobeNewsWire

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need fo...

5 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data fro...

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m.

9 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and s...

10 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

10 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumors

11 months ago - GlobeNewsWire

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Preclinical data highlights ciforadenant's mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential fi...

11 months ago - GlobeNewsWire

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Data supported CPI-818's novel immunotherapy mechanism of action and its potential to provide a platform approach to a broad range of solid and hematological cancers

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president an...

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818,...

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

1 year ago - GlobeNewsWire

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased ...

1 year ago - GlobeNewsWire

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker

1 year ago - GlobeNewsWire